Citations

Clear

4610 citation(s) found for "Lu, Brian".

Recommendations of the Blue Ribbon Committee II for the Optimization of Surgical Education and Training in the United States
Johnson, Wali R. , Mainali, Bigyan B. , Chen, Xiaodong, Martin, Rebecca , Dawson-Amoah, Kwesi G, Doyle, Kathleen M., Ellis, Danielle , Fazzone, Brian , Hoefer, Lea , Riner, Andrea N. , Shin, Thomas , Yelorda, Kirbi , Kearse, LaDonna , Chen, Xiaodong, Alobuia, Wilson Mawutor , Anderson, Erik M., Martin, Rebecca, Caldwell, Katharine E. , Dawson-Amoah, Kwesi G., Ghio, Michael , Godfrey, Caroline M. , Gomes, Camilla , Niehaus, Hannah, Phelps, Hannah M. , Sharon, Cimarron E. , Coleman, Julia R.

Mayo Clinic

Annals of Surgery | August 7, 2024 | Volume: 281 | Issue: 1 | Pages: 40-45

10.1097/sla.0000000000006483 | PMID 39109446 Get It

Objective: This study aims to appraise recommendations from an expert panel of surgical educators on optimizing surgical education and training in the setting of contemporary challenges. Background: The Blue Ribbon Committee (BRC II), a group of surgical educators, was convened to make recommendations to optimize surgical training, considering the current changes in the landscape of surgical education. Surgical trainees were recruited to assess their impressions of the recommendations. Methods: A mixed-methods study design was employed, with a survey, followed by focus group interviews. Participating residents and fellows were recruited through a purposeful sampling approach. Descriptive statistics were applied to analyze the survey data, and a thematic data analysis on interview transcripts was employed. Results: The majority of trainee respondents (n=16) thought that all of the subcommittee recommendations should be included in the final BRC II recommendations and paper. According to the interviews, overall, the feedback from the trainees was positive, with particular excitement around work-life integration, education support and faculty development, and funding pitfalls. Some themes about concerns included a lack of clarity about the recommendations, concern about some recommendations being in conflict with one another, and a disconnect between the initial BRC II survey and the subsequent recommendations. Conclusions: The residents gathered for this focus group were encouraged by the thought, effort, and intention that gathered the surgical leaders across the country to make the recommendations. While the trainees wanted clarity on some areas, the overall opinion was in agreement with the recommendations.
Utilization of Real-World Data to Facilitate Clinical Trials for Patients with Lymphoma
Hobbs, Brian P. , Flowers, Christopher R. , Chihara, Dai , Maurer, Matthew J.

Mayo Clinic

Pharmacoepidemiology | August 6, 2024 | Volume: 3 | Issue: 3 | Pages: 252-264

10.3390/pharma3030017 Get It

The future directions in leveraging real-world evidence (RWE) and real-world data (RWD) in the field of lymphoma, as compared to traditional experimental clinical trials, are poised to significantly impact research methodologies, treatment strategies, and patient care. Current methods of clinical trials involve a well-controlled design and patient selection bias. Integrating RWE and RWD with experimental clinical trials offers a multifaceted approach to understanding lymphoma and enhancing patient outcomes. In this review, we discuss how RWE has helped shape lymphoma clinical trials, and we compare and evaluate evidence obtained from real-world lymphoma studies/databases with that obtained from clinical trials. We also discuss methods for utilizing surrogate endpoints to facilitate clinical trials and expedite drug development. RWE can be leveraged to bridge the gap between data obtained from clinical trial populations and the broader patient population encountered in clinical practice, by highlighting differences in outcomes and the need for effective treatment strategies across diverse patient groups.
Snapping Biceps Femoris Repair: A Rare Cause of Lateral Knee Pain
Tagliero, Adam J. , Tadepalli, Vaibhav , Tagliero, Adam , Werner, Brian C.

Mayo Clinic

Video Journal of Sports Medicine | August 6, 2024 | Volume: 4 | Issue: 4 | Pages: No page available

10.1177/26350254241239978 | PMID 40309049 Get It

Background: Snapping biceps femoris syndrome (SFS) represents a rare clinical entity in which the biceps femoris subluxates over the fibular head in deep flexion. Two primary pathophysiologies have been described including a prominent or abnormal fibular head morphology. Others have implicated an anomalous biceps femoris insertion. The diagnosis is made clinically, with operative and nonoperative intervention strategies available for treatment. Indications: SFS often results in audible snapping and associated pain at the lateral fibular head. When recalcitrant to nonoperative management, surgical intervention can lead to resolution of symptoms. We present the case of a college-aged male who has bilateral symptoms, worse on the right, which have resulted in significant activity modification and daily discomfort recalcitrant to anti-inflammatory medication and physical therapy. Technique Description: The patient was placed supine on the operating room table with an ipsilateral bump under the hip to assist in exposure of the lateral aspect of the knee. Examination under anesthesia (EUA) confirmed the snapping biceps femoris. A lateral approach to the knee and a common peroneal neurolysis was performed. The biceps femoris insertional anatomy was examined for anomalous tendon insertion or insertional tearing. The prominent fibular head was exposed and resected, with careful attention not to disrupt the lateral collateral ligament or popliteofibular ligament insertion sites. The biceps femoris was then repaired to the prepared bony bed of the fibula with one double-loaded suture anchor. Repeat EUA confirmed complete resolution of snapping even with maximal internal rotation of the tibia; this was carefully examined again with the tourniquet deflated to ensure its compressive effect was not partially responsible for the resolution. Results: Published data pertaining to SFS is limited to case reports and small case series. With appropriate indications, surgical intervention yields promising results with a high percentage of patients returning to prior level of activity or prior participation level in sport. Discussion/Conclusion: SFS can be diagnosed with a careful clinical assessment. When recalcitrant to nonoperative management, it is effectively treated with surgical intervention to restore normal fibular anatomy, and prevent recurrent instability and persistent pain. The presented technique allows for appropriate management of these rare injuries. Patient Consent Disclosure Statement: The author(s) attests that consent has been obtained from any patient(s) appearing in this publication. If the individual may be identifiable, the author(s) has included a statement of release or other written form of approval from the patient(s) with this submission for publication.
Contemporary Practice Patterns in the Treatment of Cervical Stenosis and Central Cord Syndrome
Kazarian, Erick R., Sodha, Sonal , Rhee, John M. , Freedman, Brett A. , Sebastian, Arjun S. , Currier, Bradford L. , Levy, Hannah A. , Pinter, Zachariah W. , Fehlings, Michael G. , Freedman, Brett A. , Nassr, Ahmad , Karamian, Brian A.

Mayo Clinic

Clinical Spine Surgery | August 5, 2024 | Volume: 38 | Issue: 2 | Pages: E61-E68

10.1097/bsd.0000000000001663 | PMID 39101583 Get It

Study Design: Cross-sectional study. Objective: To evaluate for areas of consensus and divergence of opinion within the spine community regarding the management of cervical spondylotic conditions and acute traumatic central cord syndrome (ATCCS) and the influence of the patient's age, disease severity, and myelomalacia. Summary of Background Data: There is ongoing disagreement regarding the indications for, and urgency of, operative intervention in patients with mild degenerative myelopathy, moderate to severe radiculopathy, isolated axial symptomatology with evidence of spinal cord compression, and ATCCS without myelomalacia. Methods: A survey request was sent to 330 attendees of the Cervical Spine Research Society (CSRS) 2021 Annual Meeting to assess practice patterns regarding the treatment of cervical stenosis, myelopathy, radiculopathy, and ATCCS in 16 unique clinical vignettes with associated MRIs. Operative versus nonoperative treatment consensus was defined by a management option selected by >80% of survey participants. Results: Overall, 116 meeting attendees completed the survey. Consensus supported nonoperative management for elderly patients with axial neck pain and adults with axial neck pain without myelomalacia. Operative management was indicated for adult patients with mild myelopathy and myelomalacia, adult patients with severe radiculopathy, elderly patients with severe radiculopathy and myelomalacia, and elderly ATCCS patients with pre-existing myelopathic symptoms. Treatment discrepancy in favor of nonoperative management was found for adult patients with isolated axial symptomatology and myelomalacia. Treatment discrepancy favored operative management for elderly patients with mild myelopathy, adult patients with mild myelopathy without myelomalacia, elderly patients with severe radiculopathy without myelomalacia, and elderly ATCCS patients without preceding symptoms. Conclusions: Although there is uncertainty regarding the treatment of mild myelopathy, operative intervention was favored for nonelderly patients with evidence of myelomalacia or radiculopathy and for elderly patients with ATCCS, especially if pre-injury myelopathic symptoms were present. Level of Evidence: Level V.
Contemporary Outcomes and Trends for the Transseptal Mitral Valve-in-Valve Procedure Using Balloon Expandable Transcatheter Valves in the United States
Goel, Kashish , Makkar, Raj , Krishnaswamy, Amar , Kapadia, Samir , Kodali, Susheel , Shah, Ashish S. , Barker, Colin M. , Xu, Ke , Dhoble, Abhijeet , Yadav, Pradeep , Rihal, Charanjit S. , Abbas, Amr E. , Kapadia, Samir , Guerrero, Mayra E , Whisenant, Brian K. , Rihal, Charanjit S. , Guerrero, Mayra

Mayo Clinic

Circulation | August 5, 2024 | Volume: 150 | Issue: 19 | Pages: 1493-1504

10.1161/circulationaha.124.068847 | PMID 39101203 Get It

BACKGROUND: Previous transcatheter valve therapy registry analyses of transcatheter mitral valve in valve (MViV) replacement of degenerated bioprosthesis reported early experience in the United States. Given recent increases in transseptal MViV volumes and introduction of the SAPIEN 3 Ultra valve, it is important to determine contemporary outcomes for patients undergoing transseptal SAPIEN 3/SAPIEN 3 Ultra MViV replacement. METHODS: The Society of Thoracic Surgeons (STS)/American College of Cardiology Transcatheter Valve Therapy Registry was used to extract data for all patients undergoing transseptal SAPIEN 3/SAPIEN 3 Ultra MViV from 2015 to September 2022. Primary efficacy outcome was 1-year all-cause mortality. Secondary end points included 30-day mortality, functional class, quality of life, and mitral valve performance. Primary safety outcomes were device success and in-hospital complications. RESULTS: A total of 4243 patients with a mean±SD STS score of 9.2±7.7 underwent transseptal MViV at 455 sites. The rate of Mitral Valve Academic Research Consortium technical (96.6%) success was high, and procedural complications were low. All-cause in-hospital, 30-day, and 1-year mortality rates were 3.2%, 4.3%, and 13.4%, respectively. Significant improvements in New York Heart Association class (New York Heart Association I/II, 18% to 87%) and quality of life (Kansas City Cardiomyopathy Questionnaire score, 38 to 78) were noted at 1 year ( P <0.0001 for both) after MViV. Upon stratifying by STS scores, it was observed that the low-risk group (STS<4) had a significantly lower in-hospital mortality rate of 0.4%, whereas the intermediate-risk group (STS, 4–8) had an in-hospital mortality rate of 1.9%. From 2015 to 2022, the number of transseptal MViV cases/year increased significantly, whereas procedure times, length of stay, and intensive care unit hours shortened significantly. At the same time, there was a significant trend toward reduced in-hospital ( P =0.0005), 30-day ( P =0.004), and 1-year mortality rates ( P =0.01). CONCLUSIONS: This multicenter, prospective study reports excellent procedural outcomes, acceptable 1-year mortality rates, and a significant improvement in quality of life for patients undergoing transseptal MViV in the contemporary era. Patients in the low-risk and intermediate-risk STS score categories had significantly better outcomes compared with those in the high-risk category. MViV is a reasonable therapy for the majority of patients with degenerated bioprosthetic mitral valves, who are anatomical candidates.
Patient-Specific Distal Femoral Guides Optimize Cartilage Topography Matching in Osteochondral Allograft Transplantations
Elias, Tristan J. , Credille, Kevin , Wang, Zachary , Inoue, Nozomu , Orías, Alejandro A. Espinoza , Beals, Corey , Haneberg, Erik , Cole, Brian J. , Yanke, Adam B. , Haneberg, Erik C , Hevesi, Mario

Mayo Clinic

The American Journal of Sports Medicine | August 5, 2024 | Volume: 52 | Issue: 10 | Pages: 2547-2554

10.1177/03635465241261353 | PMID 39101660 Get It

Background: Osteochondral allograft (OCA) transplantation is an important surgical technique for full-thickness chondral defects in the knee. For patients undergoing this procedure, topography matching between the donor and recipient sites is essential to limit premature wear of the OCA. Currently, there is no standardized process of donor and recipient graft matching. Purpose: To evaluate a novel topography matching technique for distal femoral condyle OCA transplantation using 3-dimensional (3D) laser scanning to create 3D-printed patient-specific instrumentation in a human cadaveric model. Study Design: Descriptive laboratory study. Methods: Human cadaveric distal femoral condyles (n = 12) underwent 3D laser scanning. An 18-mm circular osteochondral recipient defect was virtually created on the medial femoral condyle (MFC), and the position and orientation of the best topography-matched osteochondral graft from a paired donor lateral femoral condyle (LFC) were determined using an in silico analysis algorithm minimizing articular step-off distances between the edges of the graft and recipient defect. Distances between the entire surface of the OCA graft and the underneath surface of the MFC were evaluated as surface mismatch. Donor (LFC) and recipient (MFC) 3D-printed patient-specific guides were created based on 3D reconstructions of the scanned condyles. Through use of the guides, OCAs were harvested from the LFC and transplanted to the reamed recipient defect site (MFC). The post-OCA recipient condyles were laser scanned. The 360° articular step-off and cartilage topography mismatch were measured. Results: The mean cartilage step-off and graft surface mismatch for the in silico OCA transplant were 0.073 ± 0.029 mm (range, 0.005-0.113 mm) and 0.166 ± 0.039 mm (range, 0.120-0.243 mm), respectively. Comparatively, the cadaveric specimens postimplant had significantly larger step-off differences (0.173 ± 0.085 mm; range, 0.082-0.399 mm; P = .001) but equivalent graft surface topography matching (0.181 ± 0.080 mm; range, 0.087-0.396 mm; P = .678). All 12 OCA transplants had mean circumferential step-off differences less than a clinically significant cutoff of 0.5 mm. Conclusion: These findings suggest that the use of 3D-printed patient-specific guides for OCA transplantation has the ability to reliably optimize cartilage topography matching for LFC to MFC transplantation. This study demonstrated substantially lower step-off values compared with previous orthopaedic literature when also evaluating LFC to MFC transplantation. Using this novel technique in a model performing MFC to MFC transplantation has the potential to yield further enhanced results due to improved radii of curvature matching. Clinical Relevance: Topography-matched graft implantation for focal chondral defects of the knee in patients improves surface matching and has the potential to improve long-term outcomes. Efficient selection of the allograft also allows improved availability of the limited allograft sources.
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Jain, Michael D. , Spiegel, Jay Y. , Nastoupil, Loretta J. , Tamaresis, John , Ghobadi, Armin , Lin, Yi , Lekakis, Lazaros J. , Oluwole, Olalekan O. , McGuirk, Joseph P. , Deol, Abhinav , Dorritie, Kathleen , Sehgal, Alison R. , Hill, Brian T. , Ulrickson, Matthew L. , Patel, Dilan A. , Jacobs, Miriam T. , Bansal, Radhika , Patel, Vivek , Rapoport, Aaron P. , Neelapu, Sattva S. , Lunning, Matthew A. , Dahiya, Saurabh , Oluwole, Olalekan O , McGuirk, Joseph , Deol, Abhinav , Goy, Andre Henri , Munoz, Javier L , Ulrickson, Matthew , Westin, Jason R , Chavez, Julio C , Patel, Dilan , Jacobs, Miriam T , Bansal, Radhika , Bennani, N Nora , Rapoport, Aaron P , Vose, Julie , Miklos, David B , Neelapu, Sattva S , Locke, Frederick L , Dahiya, Saurabh , Jain, Michael D , Lin, Yi , Nastoupil, Loretta J , Ghobadi, Armin , Reagan, Patrick Michael , Andreadis, Charalambos Babis , Muñoz, Javier , Westin, Jason R. , Bennani, N. Nora , Vose, Julie M. , Miklos, David B. , Locke, Frederick L.

Mayo Clinic

Journal of Clinical Oncology | August 2, 2024 | Volume: 42 | Issue: 30 | Pages: 3581-3592

10.1200/jco.23.02786 | PMID 39094076 Get It

PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that is approved for the treatment of relapsed or refractory large B-cell lymphoma. Little is known about the long-term survivorship after CAR T-cell therapy. METHODS We previously reported the results of 298 patients who were leukapheresed with the intent to receive standard-of-care axi-cel (n = 275 infused) after two or more previous lines of therapy at a median follow-up of 12.9 months. Here, we report extended follow-up of this cohort to a median of 58 months, with a focus on late survivorship events. RESULTS Among axi-cel–infused patients, progression-free survival at 5 years was 29% and overall survival (OS) at 5 years was 40%. The 5-year lymphoma-specific survival was 53% with infrequent late relapses. However, the 5-year nonrelapse mortality (NRM) was 16.2%, with over half of NRM events occurring beyond 2 years. Patients who were 60 years and older had a lower risk of relapse ( P = .02), but a higher risk of NRM compared with patients younger than 60 years (NRM odds ratio, 4.5 [95% CI, 2.1 to 10.8]; P < .001). Late NRM was mainly due to infections and subsequent malignant neoplasms (SMNs). In total, SMNs occurred in 24 patients (9%), including therapy-related myeloid neoplasms (n = 15), solid tumors (n = 7), and unrelated lymphoid malignancies (n = 2). CONCLUSION In the standard-of-care setting, axi-cel exhibits outcomes consistent with those reported in clinical trials, with sustained, durable responses observed at the 5-year time point. However, late infections and the development of SMN are key survivorship issues that reduce long-term survival after CAR T-cell therapy, particularly in the elderly.
Navigating the landscape of food allergies: Insights and perspectives from the AMCP Market Insights Program
Richardson, T, Gupta, Ruchi , Goldstein, Fred, Kobernick, Michael, Chan, Vivien, Wescott, Susan, Gandhi, Gaurang, Winders, Tonya , Richardson, Terry, Vickery, Brian P. , Gupta, Ruchi

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | August 1, 2024 | Volume: 30 | Issue: 8-a Suppl | Pages: S1-S10

10.18553/jmcp.2024.30.8-a.s1 | PMID 39088372 Get It

Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study
Feagan, Brian G., Matsuoka, Katsuyoshi , Rogler, Gerhard , Laharie, David , Vermeire, Séverine , Loftus, Edward V. , Beales, Ian , Schreiber, Stefan , Kim, Hyo Jong , Faes, Margaux , Haas, Angela de, Masior, Tomasz , Rudolph, Christine , Danese, Silvio , Loftus, Edward V , Beales, Ian , Schreiber, Stefan , Peyrin-Biroulet, Laurent , Vermeire, Séverine , Danese, Silvio , Peyrin‐Biroulet, Laurent , Matsuoka, K

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 1, 2024 | Volume: 60 | Issue: 5 | Pages: 563-584

10.1111/apt.18158 | PMID 39086130 Get It

SummaryBackgroundFilgotinib, an oral, once‐daily, Janus kinase 1 preferential inhibitor, is an approved treatment for moderately to severely active ulcerative colitis.AimsThe aim of this study is to assess the safety and efficacy of continued filgotinib therapy over ~4 years in the long‐term extension of the phase 2b/3 SELECTION trial (SELECTIONLTE; NCT02914535).MethodsIn this interim analysis of SELECTIONLTE, SELECTION completers (week 10 responders to filgotinib who completed the maintenance study) continued their assigned treatment (double‐blind filgotinib 200 mg [FIL200] or filgotinib 100 mg) and SELECTION week 10 non‐responders received open‐label FIL200. We assessed safety by adverse events (AEs), and efficacy by partial Mayo Clinic Score (pMCS), inflammatory biomarkers and health‐related quality of life (HRQoL). We compared safety and efficacy between achievers and non‐achievers of a multi‐component endpoint, comprehensive disease control (CDC), comprising symptomatic, endoscopic, inflammatory biomarker and HRQoL improvements.ResultsData for completers (n = 250) and non‐responders (n = 372) were reported for ≤202 weeks. AE occurrences were low and consistent with previous analyses. The as‐observed proportion of FIL200‐treated patients in pMCS, biomarker and HRQoL remission during SELECTIONLTE remained high among completers (week 144: 80.0%, 86.4% and 86.0%, respectively) and increased among non‐responders (week 192: 62.1%, 76.7% and 59.3%, respectively). Significantly higher proportions of CDC achievers at SELECTION week 58 achieved pMCS, IBDQ and corticosteroid‐free pMCS remission than non‐achievers, up to LTE week 96.ConclusionsFilgotinib induced and maintained symptomatic remission and improved HRQoL over 4 years. Safety results showed a proven long‐term benefit–risk profile. FIL200‐treated CDC achievers had better long‐term outcomes than non‐achievers.
A Contemporary Review of Blood Transfusion in Critically Ill Patients
Yadav, Sumeet K. , Hussein, Guleid , Liu, Bolun , Vojjala, Nikhil , Warsame, Mohamed , Labban, Mohamad El , Rauf, Ibtisam , Zareen, Tashfia, Zhang, Y , Jain, Shika M., Surani, Salim , Devulapally, Pavan , Bartlett, Brian, Khan, Syed Anjum , Jain, Nitesh , El Labban, Mohamad , Zhang, Yaqi , Surani, Salim , Devulapally, Pavan , Khan, Syed Anjum , Jain, Nitesh Kumar , Yadav, Sumeet Kumar , Liu, Bolun , Hassan, Mohamed Sayed , Usama, Syed Muhammad, Jain, Shika M

Mayo Clinic

Medicina | July 31, 2024 | Volume: 60 | Issue: 8 | Pages: 1247

10.3390/medicina60081247 | PMID 39202529 Get It

Blood transfusion is a common therapeutic intervention in hospitalized patients. There are numerous indications for transfusion, including anemia and coagulopathy with deficiency of single or multiple coagulation components such as platelets or coagulation factors. Nevertheless, the practice of transfusion in critically ill patients has been controversial mainly due to a lack of evidence and the need to consider the appropriate clinical context for transfusion. Further, transfusion carries many risk factors that must be balanced with benefits. Therefore, transfusion practice in ICU patients has constantly evolved, and we endeavor to present a contemporary review of transfusion practices in this population guided by clinical trials and expert guidelines.